Future Directions and Priorities for Cellular Therapy in Sarcoma: A Report from the Strategic Advances in Sarcoma Science Cell Therapy Breakout
Authors:
- Jacqueline Oliva-RamirezJOJacqueline Oliva-Ramirez
- David MilewskiDavid Milewski
- Lauren BanksLBLauren Banks
- Kelly M. BaileyKBKelly M. Bailey
- Everett J. ModingEMEverett J. Moding
- Jessica LakeJLJessica Lake
- Alice ChenACAlice Chen
- Jessica D. DaleyJDJessica D. Daley
- Erin E. ReschERErin E. Resch
- Rosandra N. KaplanRKRosandra N. Kaplan
- Brian H. LadleBLBrian H. Ladle
- Lindy ZhangLZLindy Zhang
Open Access
Abstract
Background: In September of 2024, the 2nd annual meeting of the Strategic Advances in Sarcoma Science (SASS) convened at the National Institutes of Health. This gathering of national sarcoma experts focused on preclinical studies, clinical trials, opportunities, challenges, and future directions in sarcoma biology and clinical care with a focus on immunotherapy. The Immunology in Sarcoma breakout group conducted a dedicated discussion focused on the current and future implementation of adoptive cellular therapies (ACTs) in sarcomas. The current manuscript summarizes these discussions and provides a comprehensive resource for researchers and clinicians. Results: Adoptive cell therapy (ACT) has shown encouraging results in sarcomas with afami-cel achieving durable responses in synovial sarcoma and early TCR-T trials against NY-ESO-1 and MAGE-A4 demonstrating meaningful response rates. Building on these outcomes will require discovering new targets, selecting optimal cell types, refining conditioning regimens, combining with alternative treatment strategies such as TKIs, and leveraging predictive biomarkers informed by a deeper understanding of the tumor microenvironment. Conclusions: Sarcomas are promising targets for adoptive cell therapy (ACT), as shown by afami-cel’s success in synovial sarcoma, but broader impact requires new target discovery, optimal cell selection, improved conditioning, combination treatments, deeper tumor microenvironment understanding, and predictive biomarkers to achieve more durable responses for more patients.Keywords
Funding Information
- NIH/NCI SPORE (1P50CA272170)
This publication has 144 references indexed in Scilit:
- FDA-Approved Chimeric Antigen Receptor (CAR)-T Cell Therapy for Different Cancers-A Recent PerspectiveMolecular Biotechnology, 2024
- Toll-Like Receptor 4 Agonist Injection With Concurrent Radiotherapy in Patients With Metastatic Soft Tissue SarcomaJAMA Oncology, 2023
- Cancer biology deciphered by single-cell transcriptomic sequencingProtein & Cell, 2021
- Gene fusion neoantigens: Emerging targets for cancer immunotherapyCancer Letters, 2021
- Ultra‐rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entitiesCancer, 2021
- Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint BlockadeCancer Cell, 2020
- Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid TumorsCancer Cell, 2020
- Cancer testis antigens in sarcoma: Expression, function and immunotherapeutic applicationCancer Letters, 2020
- Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy2016
- Prognostic factors for patients with localized soft‐tissue sarcoma treated with conservation surgery and radiation therapyCancer, 2003